MDxHealth price target lowered to $8 from $12 at BTIG

BTIG analyst Mark Massaro lowered the firm’s price target on MDxHealth to $8 from $12 and keeps a Buy rating on the shares. The company’s Q4 was in line with its pre-announcement, and MDxHealth looks to have strengthened its balance sheet, is seeing a lift from new tests, and is close to activating Medicare payment for its SelectMDx test, the analyst tells investors in a research note. The firm adds however that its reduced price target reflects MDxHealth’s equity raise.